Craig Woods is a clinical researcher and business developer with over 20 years of experience in conducting human and veterinary clinical trials, regulatory affairs (FDA, USDA), technology licensing, due diligence, and contract negotiations. Craig joined the Institute for Future Health in June of 2021. In his current capacity, Craig is focused on aligning the resources and expertise of Arizona's public universities with the needs of external partners (hospitals, industry, etc.) to address major infectious disease and biosecurity challenges.
From 2015-2021, Craig served as the Director of Midwestern University's Institute for Healthcare Innovation. During this time, Craig directed the clinical research program for University clinics and external community hospitals including human phase II-IV clinical trials, veterinary clinical studies, and translational research projects. During this time, Craig served as a clinical investigator on infectious diseases (anti-infectives, SARS-CoV-2) and comparative & translational studies in the areas of envenomation, oncology, neurology, orthopedics, and cardiovascular disease.
From 1998-2015, Craig held senior level positions in business development and R&D within the pharmaceutical industry. During this time, he was responsible for leading due diligence and licensing negotiations for various pharmaceuticals, biologics, and medical devices. Craig also founded several start-up biomedical companies, leading the licensing, development and commercialization of first-in-class medical technologies. Craig's work in comparative ophthalmology and biomaterials led to the development and commercialization of a novel subscleral (suprachoroidal) glaucoma implant for humans.
From 1995-1998, Craig was in small animal clinical practice in Tucson, AZ and Fountain Hill, AZ, and remains a licensed veterinarian in Arizona.
- Research: infectious disease, biosecurity, drug development, and venoms & toxins.
- Clinical: study management, study documentation and protocol development.
- Business: contract design, negotiations, valuation models, and business strategy
- Regulatory: clinical research management and compliance (HIPAA, GCP, VICH, ICH)
- BS - Biology; University of Missouri
- MS - Veterinary Anatomy; University of Missouri
- DVM - Veterinary Medicine; University of Missouri
- MBA - Business Administration; Arizona State University
- Arizona Veterinary Medical License (1995-current)
Current Research Focus: My current areas of research are directed at establishing multi-disciplinary teams to address infectious diseases, zoonosis, and pathogen surveillance and improving biosecurity measures. In this capacity, I work with multiple stakeholders (e.g., academia, industry, healthcare networks, and government agencies) to address major healthcare challenges, identify funding mechanisms, and serve to manage (direct) the respective projects.
Prior Clinical Research:
- Comparative medicine and translational research (infectious diseases, ophthalmology, cardiology, orthopedics, pain management, and other therapeutic categories)
- Clinical trials (PII-PIV): overall management and logistics for interventional and observations human subjects research.
- Toxinology: pit viper envenomation and antivenom development.
- Witsil AJ, Wells RJ, Woods CW, and Rao S. 272 cases of rattlesnake envenomation in dogs: demographics and treatment including safety of F(ab’)2 antivenom. Toxicon. 2015 Oct Vol105: 19-26.
- Peterson ME, Woods CW, Seibold KE, and Schaer M. Confounding in study of antivenoms. J Am Vet Med Assoc. 2013 Dec 1;243(11):1516.
- Woods CW and Young DA. F(ab’)2 Antivenom: Clinical Safety in Dogs. J. Vet Em Crit Care, Oct 2011.
- Woods CW, Seibold K. Problems with Antivenom Study; Letter. J. Vet Em Crit Care, Oct 2010.
- Terry DE, Rees-Milton K, Smith P, Carran J, Pezeshki P, Woods CW, Greer P, Anastassiades TP. N-acylation of glucosamine modulates chondrocyte growth, proteoglycan synthesis, and gene expression. J Rheumatol. 2005 Sep; 32 (9):1775-86.
Human Clinical Studies (2020-2021)
- Testing the efficacy and safety of [drug] in patients with SARS-CoV-2; Role: Study Site Director
- Multiplexed in-solution serological test for SARS-CoV-2 and other respiratory pathogens; Role: Site Prinicipal Investigator
- SARS-CoV-2 longitudinal immunosurveillance of emergency room providers; Role: Co-Principal Investigator
- COVID-19 - secondary use and analysis of patient biospecimens; Role: Co-Principal Investigator
Scientific Abstracts and Oral Presentations
- Woods CW. Review: Veterinary Regenerative Medicine and Tissue Engineering. Oral Abstract. Tissue Engineering and Regenerative Medicine International Society Conference (TERMIS). Dec. 13, 2016
- Woods CW. Review: The Dog as a Translational Model for Envenomation. Oral Abstract. Venom Week 2016, Toxicon Volume 117, July 2016, Page 107.
- Wells R and Woods CW. F(ab’)2 Antivenom Treatment: A Retrospective Analysis of 180 Rattlesnake Envenomations in Dogs: Oral abstract - IVECCS September 2013, San Diego.
- Falcone K, Klaus J, Mulligan K, Woods CW: Retrospective Study of F(ab’)2 Antivenom in 61 Dogs and 15 Cats Envenomated by Arizona Rattlesnakes, Oral Abstract. IVECCS 2012.
- Woods CW. Anti-Endotoxin Effects and Pharmacology of the Immune Selective Anti-Inflammatory Derivatives. Venom Week 2012; Oral Abstract – Toxicon Volume 60(2), 2012.
- Seibold KE, Woods CW, and Wells RJ. F(ab’)2 Antivenom in Dogs Envenomated by Pit Vipers. Venom Week 2012; Oral Abstract – Toxicon Volume 60(2), 2012.
- Woods CW, Seibold KE, Wells RJ. Crotalidae Venom Levels in Dogs Before and After Administration of F(ab’)2 Antivenom. Venom Week 2012; Oral Abstract – Toxicon Volume 60(2), 2012.
- K. Seibold, C. Woods, R. Wells, M. Lagutchik, et al.B. Vasilopulos. Neutralizing effects of F(ab’)2 antivenom on serum pit viper venom levels in dogs. Oral Abstract. Nashville, TN. IVECCS 2011.
- Gingerich DA, and Woods, CW. T-cell Receptor Peptide Therapeutics for Feline Stomatitis; Oral Abstract, Am. Assoc. of Vet. Pharmacology and Therapeutics – 2011 Conference.
- K.Seibold, A. Reniker, R. Wells, M. Lagutchik, S. Johnson, D. Bordelon, M. Clare, M. Kaelble, R. Vasilopulous, and C. Woods; Evaluation of an Antivenom F(ab’)2 in 74 Dogs Envenomated by North American Pit Vipers. Abstract; San Antonio; IVECCS 2010.
- Woods, C, Godine, R and Huber B. apSTAR Cancer Laser: Review of Immunological Effects and Case Reports. Veterinary Cancer Society Mid-Year Meeting; 2010.
- Woods, CW. Use of TCR Peptides for Feline Stomatitis. 23rd Annual Veterinary Dental Forum: 2009.
- Woods, CW. Tissue Repair BioScaffold; Clinical Review. 23rd Annual Veterinary Dental Forum: 2009.
- Urbanz, J and Woods, CW. Effects of an Embryonic-like BioScaffold on Canine Indolent Ulcer. Abstract Presentation; Am. College of Vet. Ophthalmologists 2009; Chicago, IL.
- Roberts SW and Woods, CW. The Use of a Novel Porous Implant for Refractory Canine Glaucoma. Abstract Presentation; Am. College of Vet. Ophthalmologists Conference 2008; Boston, MA.
- Urbanz, J and Woods, CW. The Use of a Novel Biomaterial for Refractory Canine Dry Eye; 2006 Am. College of Veterinary Ophthalmologists Conference 2006.
- Howard Hughes Undergraduate Medical Fellowship (1989-1990)
- Veterinary Biomedical Research Fellowship (1991-1992)
ad hoc Reviewer
- Journal of the American Veterinary Medical Association
- Arizona Veterinary Medical Association (1995-present)
- American Veterinary Medical Association (1995-present)
- North American Society of Toxinology
- International Society of Toxinology
- Board of Directors - United Cerebral Palsy Foundation of Arizona
- Organizing Chair - Venom Week VIII 2022
- Veterinary Co-Chair - Venom Week V and 17th Annual World Toxinology Society Conference